Xofigo
Payments companies reported to CMS as associated with Xofigo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xofigo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xofigo
These are the largest totals companies reported as associated with Xofigo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Vijay Gunuganti | San Antonio, TX | Medical Oncology | $90,499.26 |
| Pedro Barata | New Orleans, LA | Hematology & Oncology | $38,451.39 |
| Shawn Zimberg | Plainview, NY | Radiation Oncology | $35,017.38 |
| Przemyslaw Twardowski | Santa Monica, CA | Medical Oncology | $31,842.87 |
| Christopher Lee | Spokane Valley, WA | Radiation Oncology | $30,834.91 |
| Matthew Rettig | Los Angeles, CA | Hematology & Oncology | $29,510.08 |
| Evan Yu | Seattle, WA | Medical Oncology | $26,658.80 |
| Phuoc Tran | Houston, TX | Radiation Oncology | $26,531.12 |
| Edward Uchio | Orange, CA | Urology | $25,153.82 |
| David Diamond | Winter Park, FL | Radiation Oncology | $23,645.63 |
Prescribed Xofigo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.